Effects of Salmeterol/Fluticasone on Bone Metabolism and Bone Density in the Patients with Moderate Chronic Obstructive Pulmonary Disease(COPD)
10.3969/j.issn.0253-9896.2014.10.020
- VernacularTitle:中度慢性阻塞性肺疾病患者吸入沙美特罗替卡松对骨代谢的影响
- Author:
Xuemei HAN
;
Yanping LAI
;
Xia YANG
- Publication Type:Journal Article
- Keywords:
lung diseases,obstructive;
albuterol;
bone density;
osteocalcin;
alkaline phosphatase;
salmeterol fluticasone
- From:
Tianjin Medical Journal
2014;(10):1029-1031
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of salmeterol/fluticasone on the bone metabolism and bone density of the patients with moderate COPD and whether the effects is relate with inhaled corticosteroid course. Methods Sixty pa-tients with COPD were divided into 2 groups by random digit table. Patients in experimental group (n=30) were given conven-tional therapy with salmeterol/fluticasone one inhale(bid) for continuously 12 months while patients in control group (N=30) were given conventional therapy without any glucocorticoid.The bone mineral density (BMD) of the femoral triangle in all patients were measured by DXA before therapy, 3 months and 12 months after therapy. At the same time, biochemical indi-cators that are correlated with bone metabolism include bone gla protein (BGP) and alkaline phosphatase (ALP) were mea-sured by radioimmunoassay. Results The BMD, BGP and ALP of patients in experimental group and in control group be-fore therapy, 3 month and 12 month after therapy were compared. There is no significant difference (P>0.05) between these two groups before therapy and after 3 month but significant difference was shown after 9 months (P<0.05). Conclusion Short period inhaling salmeterol/fluticasone in patients with COPD is safe. But long-term inhaling salmeterol/fluticason may lead to decline of the bone density in patients with COPD.
